Neurobo Pharmaceuticals is a biotechnology business based in the US. Neurobo Pharmaceuticals shares (NRBO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.40 – an increase of 0.42% over the previous week. Neurobo Pharmaceuticals employs 8 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.40 |
|---|---|
| 52-week range | $2.08 - $6.75 |
| 50-day moving average | $2.98 |
| 200-day moving average | $3.92 |
| Wall St. target price | $26.67 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-4.01 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.45 from 2024-11-19
| 1 week (2024-11-14) | 2.51% |
|---|---|
| 1 month (2024-10-21) | -16.10% |
| 3 months (2024-08-21) | -35.01% |
| 6 months (2024-05-21) | -46.51% |
| 1 year (2023-11-21) | 469.77% |
|---|---|
| 2 years (2022-11-21) | -75.69% |
| 3 years (2021-11-19) | 381.6 |
| 5 years (2019-11-21) | 2118 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -74.35% |
| Return on equity TTM | -160.76% |
| Profit margin | 0% |
| Book value | $1.51 |
| Market Capitalization | $20.6 million |
TTM: trailing 12 months
We're not expecting Neurobo Pharmaceuticals to pay a dividend over the next 12 months.
Neurobo Pharmaceuticals's shares were split on a 1:8 basis on 20 December 2023 . So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Neurobo Pharmaceuticals shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Neurobo Pharmaceuticals shares which in turn could have impacted Neurobo Pharmaceuticals's share price.
Over the last 12 months, Neurobo Pharmaceuticals's shares have ranged in value from as little as $2.08 up to $6.75. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Neurobo Pharmaceuticals's is -0.28. This would suggest that Neurobo Pharmaceuticals's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Neurobo Pharmaceuticals has bucked the trend.
NeuroBo Pharmaceuticals, Inc. , a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene; and joint research agreement with Dong-A ST and ImmunoForge for the development of DA-1726. NeuroBo Pharmaceuticals, Inc.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.